KLK6

Kallikrein-6 · Q92876 · KLK6 on Sugi Atlas →

4,653 patent compounds predicted against KLK6, 2,358 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1829151	0.56	10/20
Hydrochloric Acid (SCHEMBL4888001)	0.50	10/20
SCHEMBL3290446	0.56	8/20
SCHEMBL1553522	0.63	7/20
SCHEMBL3882162	0.47	7/20
SCHEMBL3879451	0.54	6/20
SCHEMBL111906	0.53	6/20
SCHEMBL6287385	0.48	6/20
SCHEMBL6415721	0.47	6/20
SCHEMBL4548528	0.45	6/20
SCHEMBL3881597	0.44	6/20
SCHEMBL3881381	0.42	6/20
SCHEMBL4530083	0.42	6/20
SCHEMBL6433868	0.38	6/20
Hydrochloric Acid (SCHEMBL6707045)	0.48	5/20
Trifluoroacetic Acid (SCHEMBL2331702)	0.91	4/20
Trifluoroacetic Acid (SCHEMBL2331706)	0.91	4/20
Trifluoroacetic Acid (SCHEMBL2335734)	0.90	4/20
Trifluoroacetic Acid (SCHEMBL2326762)	0.89	4/20
Trifluoroacetic Acid (SCHEMBL2326764)	0.89	4/20

Clinical trials — most relevant to KLK6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein	PHASE4	UNKNOWN
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II	PHASE3	COMPLETED
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)	PHASE3	ACTIVE_NOT_RECRUITING
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer	PHASE2	COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA	PHASE1/PHASE2	RECRUITING
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	PHASE2	COMPLETED
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke	PHASE2	COMPLETED
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME	PHASE1	COMPLETED
A Phase I Clinical Study of a Single Dose of KLA480	PHASE1	RECRUITING
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21	PHASE1	COMPLETED
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population	nan	RECRUITING
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)	nan	ENROLLING_BY_INVITATION
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland	nan	UNKNOWN
Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)	nan	RECRUITING
The Role of KL-6 in the Clinical Diagnosis of ILD	nan	COMPLETED
Predicting Prostate Biopsy Results With Biomarkers and mpMRI.	nan	COMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer	nan	COMPLETED
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke	nan	NOT_YET_RECRUITING
Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis	nan	RECRUITING
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia	nan	COMPLETED
DKK3 for Prognosis and Monitoring of GFR Decline in Heart Failure	nan	COMPLETED
Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration	nan	UNKNOWN
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease	nan	COMPLETED
Vitamin K2 for Reduction the Calcium at Carotid Bifurcation in Patients With Subcritical Lesions	nan	COMPLETED
Utility of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Predicting Renal Impairment, Further Decompensation and Rehospitalization in Acutely Decompensated and Chronic Heart Failure Patients	nan	COMPLETED
Klotho _ LRP-6 _ Gastric Adenocarcinoma	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KLK6 binder may also engage these)

Protein	Name	Similarity
KLK2	Kallikrein-2	0.986	landscape →
KLK3	Prostate-specific antigen	0.986	landscape →
P50341	—	0.983	P50341 →
Q28773	—	0.983	Q28773 →
Q07276	—	0.983	Q07276 →
P09582	—	0.983	P09582 →
P56435	—	0.983	P56435 →
KLK7	Kallikrein-7	0.982	landscape →
KLK1	Kallikrein-1	0.982	landscape →
KLK13	Kallikrein-13	0.981	landscape →
P97592	—	0.981	P97592 →
A7WPL7	—	0.980	A7WPL7 →
P33619	—	0.980	P33619 →
O46683	—	0.980	O46683 →
P51779	—	0.979	P51779 →
P50342	—	0.979	P50342 →
Q3T0A3	—	0.979	Q3T0A3 →
P21842	—	0.979	P21842 →
P09650	—	0.979	P09650 →
Q9H2R5	—	0.979	Q9H2R5 →
P80219	—	0.978	P80219 →
P50339	—	0.978	P50339 →
O35205	—	0.978	O35205 →
P36369	—	0.977	P36369 →
Q76B45	—	0.976	Q76B45 →
P21844	—	0.976	P21844 →
P79204	—	0.976	P79204 →
TPSAB1	Tryptase beta-1	0.976	landscape →
P21812	—	0.976	P21812 →
P52195	—	0.975	P52195 →